

# Canntab Therapeutics Now Trading on the OTCQX Best Market

*Canntab upgrades to the OTCQX Best Market for Better Investor Visibility*

TORONTO, May 1, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:[PILL.CN](#)) (OTCQX:[CTABF](#)) (FRA:[TBF1.F](#)) (the "Company" or "Canntab"), the Canadian leader in hard pill oral dose therapeutic cannabis, is pleased to announce that it has qualified for, and is now trading on, the OTCQX Best Market in the United States under the symbol "CTABF."

"Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. This move also coincides with Canntab reaching a major milestone in April which has opened the door for Canadian and international sales and white labeling," explains Richard Goldstein, co-founder and Chief Financial Officer of Canntab.

"Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary processes," says Jeff Renwick, co-founder and Chief Executive Officer of Canntab.

Canntab is well positioned in the emerging medical cannabis market with 13 patents pending in the United States and Canada covering a range of proprietary processes and formulations. In addition, the company is currently scaling up manufacturing at their Cobourg facility while moving through the regulatory processes with the intention of bringing a full suite of products to market in Canada and the United States, pending Health Canada approval.

**About Canntab**

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

## **Forward Looking Statements**

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the "CSE") nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

**NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21.**

View original content:<http://www.prnewswire.com/news-releases/canntab-therapeutics-now-trading-on-the-otcqx-best-market-300841749.html>

SOURCE Canntab Therapeutics Limited

View original content:

<http://www.newswire.ca/en/releases/archive/May2019/01/c5574.html>

%SEDAR: 00031120E

**For further information:** Canntab Therapeutics Limited, Jeffrey Renwick, Chief Executive Officer, +1 289.301.3812, [jeff@canntab.ca](mailto:jeff@canntab.ca); Frank Candido, Business Development Consultant, 514-969-5530, [frank@directmtl.com](mailto:frank@directmtl.com), [frank.candido@sympatico.ca](mailto:frank.candido@sympatico.ca); Investor Relations, Relations Publiques Paradox Inc., Jean-Francois Meilleur, 1-866-460-0408, [jfmeilleur@paradox-pr.ca](mailto:jfmeilleur@paradox-pr.ca), <https://www.paradox-pr.ca>

CO: Canntab Therapeutics Limited

CNW 08:30e 01-MAY-19